Novartis Ag (NVS) Return on Capital Employed (2009 - 2010)
Novartis Ag (NVS) posted Return on Capital Employed of 0.0% for Q1 2010, down 100.0% sequentially from 0.0% in Q4 2009, and down 5039.0% YoY from 0.0% in Q1 2009.
Novartis Ag (NVS) Return on Capital Employed (2009 - 2010) Analysis & Trends
Novartis Ag (NVS) has 2 years of Return on Capital Employed data on file, last reported at 0.0% in Q1 2010.
- Quarterly Return on Capital Employed fell 5039.0% year-over-year to 0.0% in Q1 2010, while the trailing twelve-month figure through Mar 2010 was 0.0% (down 5039.0% YoY) and the FY2025 annual result came in at 22.24%, up 216.0% from the prior year.
- Return on Capital Employed fell to 0.0% in Q1 2010 per NVS's latest filing, from 0.0% in the prior quarter.
- The five-year high for Return on Capital Employed was 50.39% in Q1 2009, with the low at 0.0% in Q1 2010.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 42.94% |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 28.18% |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 16.47% |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 9.76% |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -5.22% |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 15.87% |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 21.53% |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -10.20% |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | -3.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2010 | 5.50% |
| Dec 31, 2009 | 10,180,430.11% |
| Sep 30, 2009 | 3,010,980.21% |
| Jun 30, 2009 | 8.98% |
| Mar 31, 2009 | 18.68% |